Literature DB >> 26151585

Patterns of use of other drugs among those with alcohol dependence: Associations with drinking behavior and psychopathology.

Howard B Moss1, Risë B Goldstein1, Chiung M Chen2, Hsiao-Ye Yi2.   

Abstract

INTRODUCTION: Alcohol dependence (AD) presents with substantial clinical heterogeneity, including concurrent use of non-alcohol drugs. Here, we examine specific patterns of concurrent non-alcohol substance use during the previous year among a nationally representative sample of adults with DSM-IV AD, and estimate their population prevalence in the U.S. We then evaluate alcohol use behavior and comorbid psychopathology among respondents with AD according to their patterns of concurrent non-alcohol substance use.
METHODS: These analyses utilized data from Waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. Latent class analyses classified respondents with AD into four clinically meaningful patterns of concurrent substance use: (1) use of alcohol only; (2) use of alcohol and tobacco only; (3) use of alcohol, tobacco and cannabis; and (4) use of alcohol, tobacco, cannabis, cocaine, and other illicit drug(s).
RESULTS: Among AD respondents, the most prevalent pattern was the use of alcohol and tobacco only (weighted percentage, 32.4%), followed by the use of alcohol only (weighted percentage, 27.5%). AD respondents who used alcohol, tobacco, cannabis, cocaine, and other illicit drug(s) (weighted percentage, 25.3%) manifested the most severe pattern of alcohol consumption, and had significant overrepresentations of major depression, panic, and other anxiety disorders as well as paranoid, schizotypal, borderline, antisocial, and histrionic personality disorders compared with those who used alcohol alone.
CONCLUSIONS: Specific patterns of concurrent substance use convey important information regarding the clinical presentation and prognosis for AD. In particular, concurrent use of illicit drugs over the past year by AD individuals was associated with greater severity and comorbid psychopathology. These data suggest the need for pragmatic trials of AD interventions that take into account patterns of substance use behavior in addition to an AD diagnosis. Published by Elsevier Ltd.

Entities:  

Keywords:  Alcohol dependence; Alcohol use; Drug use; Polysubstance use; Psychopathology

Mesh:

Year:  2015        PMID: 26151585      PMCID: PMC4515391          DOI: 10.1016/j.addbeh.2015.06.041

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  37 in total

1.  Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance.

Authors:  K K Downey; T C Helmus; C R Schuster
Journal:  Exp Clin Psychopharmacol       Date:  2000-05       Impact factor: 3.157

2.  The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment.

Authors:  P A DeMaria; R Sterling; S P Weinstein
Journal:  Am J Addict       Date:  2000

3.  Common liability to drug addictions: theory, research, practice.

Authors:  Michael M Vanyukov; Ty A Ridenour
Journal:  Drug Alcohol Depend       Date:  2012-02-05       Impact factor: 4.492

4.  Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity.

Authors:  T F Babor; M Hofmann; F K DelBoca; V Hesselbrock; R E Meyer; Z S Dolinsky; B Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1992-08

5.  Early adolescent patterns of alcohol, cigarettes, and marijuana polysubstance use and young adult substance use outcomes in a nationally representative sample.

Authors:  Howard Barry Moss; Chiung M Chen; Hsiao-Ye Yi
Journal:  Drug Alcohol Depend       Date:  2013-12-31       Impact factor: 4.492

6.  Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory.

Authors:  D B Kandel; K Yamaguchi; K Chen
Journal:  J Stud Alcohol       Date:  1992-09

7.  The long-term outcomes of drug use by methadone maintenance patients.

Authors:  Gregory Bovasso; John Cacciola
Journal:  J Behav Health Serv Res       Date:  2003 Jul-Sep       Impact factor: 1.505

8.  Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan
Journal:  Arch Gen Psychiatry       Date:  2004-08

9.  The Alcohol Use Disorder and Associated Disabilities Interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample.

Authors:  B F Grant; T C Harford; D A Dawson; P S Chou; R P Pickering
Journal:  Drug Alcohol Depend       Date:  1995-07       Impact factor: 4.492

10.  The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample.

Authors:  Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

View more
  32 in total

1.  Cigarette Smoking, Mental Health, and Other Substance Use among Court-Involved Youth.

Authors:  Anna Harrison; Danielle Ramo; Sharon M Hall; Vanessa Estrada-Gonzalez; Marina Tolou-Shams
Journal:  Subst Use Misuse       Date:  2019-11-25       Impact factor: 2.164

2.  Hazardous Alcohol Use Associated with Increased Sexual Risk Behaviors Among People Who Inject Drugs.

Authors:  Nadia Fairbairn; Kanna Hayashi; M-J Milloy; Seonaid Nolan; Paul Nguyen; Evan Wood; Thomas Kerr
Journal:  Alcohol Clin Exp Res       Date:  2016-09-17       Impact factor: 3.455

3.  Heterogeneity in the Co-occurrence of Substance Use and Posttraumatic Stress Disorder: A Latent Class Analysis Approach.

Authors:  Ateka A Contractor; Nicole H Weiss; Katherine L Dixon-Gordon; Heidemarie Blumenthal
Journal:  J Dual Diagn       Date:  2019-03-06

4.  Structural Neuroimaging in Polysubstance Users.

Authors:  Dieter J Meyerhoff
Journal:  Curr Opin Behav Sci       Date:  2017-02

5.  Psychiatric, Demographic, and Brain Morphological Predictors of Relapse After Treatment for an Alcohol Use Disorder.

Authors:  Timothy C Durazzo; Dieter J Meyerhoff
Journal:  Alcohol Clin Exp Res       Date:  2016-11-24       Impact factor: 3.455

6.  Clinical presentations, social functioning, and treatment receipt among individuals with comorbid life-time PTSD and alcohol use disorders versus drug use disorders: findings from NESARC-III.

Authors:  Tracy L Simpson; Peter Rise; Kendall C Browne; Keren Lehavot; Debra Kaysen
Journal:  Addiction       Date:  2019-03-10       Impact factor: 6.526

7.  Clinical characteristics of alcohol combined with other substance use disorders in an American Indian community sample.

Authors:  David A Gilder; Gina M Stouffer; Philip Lau; Cindy L Ehlers
Journal:  Drug Alcohol Depend       Date:  2016-02-08       Impact factor: 4.492

8.  Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity?

Authors:  Eduardo Roque Butelman; Silvia Bacciardi; Angelo Giovanni Icro Maremmani; Maya Darst-Campbell; Joel Correa da Rosa; Mary Jeanne Kreek
Journal:  Am J Addict       Date:  2017-06-27

9.  Identification of Distinct Latent Classes Related to Sleep, PTSD, Depression, and Anxiety in Individuals Diagnosed With Severe Alcohol Use Disorder.

Authors:  Gwenyth R Wallen; Jumin Park; Michael Krumlauf; Alyssa T Brooks
Journal:  Behav Sleep Med       Date:  2018-01-29       Impact factor: 2.964

10.  Adverse impact of marijuana use on clinical outcomes among psychiatry patients with depression and alcohol use disorder.

Authors:  Amber L Bahorik; Cynthia I Campbell; Stacy A Sterling; Amy Leibowitz; Adam Travis; Constance M Weisner; Derek D Satre
Journal:  Psychiatry Res       Date:  2017-10-19       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.